| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 13 May 2026 | 7 May 2026 |
| Onesource Specialty Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2026 inter alia to consider and approve the Audited Standalone and Consolidated Financial results for March 31 2026 Intimation of the outcome of the Board meeting dated May 13, 2026 for approval of the Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026 Allotment of 3,150 Equity Shares of Re.1/- each under ONESOURCE ESOP SCHEME 2021. (As per BSE Announcement dated on: 13.05.2026) | ||
| Board Meeting | 6 Mar 2026 | 6 Mar 2026 |
| Update on Composite Scheme of Arrangement and Amalgamation( Merger by Absorption) amongst Steriscience Specialties Private Limited, Brooks Steriscience Limited, Steriscience Pte. Ltd, Strides Pharma Services Private Limited and OneSource Specialty Pharma Limited and their respective shareholders. | ||
| Board Meeting | 23 Jan 2026 | 19 Jan 2026 |
| Quarterly Results Onesource Specialty Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2026 ,inter alia, to consider and approve Approval of unaudited financial results of the Company for the quarter ended December 31, 2025. Outcome of the Board meeting approving the unaudited financial results for the quarter ended December 31, 2025 (As Per BSE Announcement Dated on:23.01.2026) | ||
| Board Meeting | 11 Nov 2025 | 5 Nov 2025 |
| Onesource Specialty Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2025 inter alia to consider and approve the financial results for the quarter and half year ended September 30 2025. Outcome of the Board Meeting held on 11/11/2025 to approve the financial results for the quarter and half year ended September 30, 2025. Financial Results for the quarter and half year ended September 30, 2025 (As Per BSE Announcement Dated on:11.11.2025) | ||
| Board Meeting | 4 Aug 2025 | 29 Jul 2025 |
| Onesource Specialty Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2025 inter alia to consider and approve the standalone and consolidated financial results for the quarter ended June 30 2025 The Board has approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2025 (As Per BSE Announcement Dated on :04.08.2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
